Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: A population based study

Journal of Cancer

Volumn 5, Issue 2, 2014, Pages 151-155

  Chen, Ju Yin ^a,b   Kuo, Shou Jen ^b   Liaw, Yung Po ^c   Avital, Itzhak ^d   Stojadinovic, Alexander ^d   Man, Yan Gao ^d   Mannion, Ciaran ^e   Wang, Jianlian ^f   Chou, Ming Chih ^c,g   Tsai, Horng Der ^b   Chen, Shou Tung ^b   Hsiao, Yi Hsuan ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d Bon Secours Health System   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; TAIWAN; TREATMENT DURATION;

EID: 84893554610     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8412     Document Type: Article

References (13)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C,Godwin J, Gray R, Clarke M, Cutter D, Darby S, Mcgale P, Pan HC, Taylor C,Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-784.
2. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343:448-452.
3. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91:1654-1662.
4. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005; 97:375-384.
5. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries Jones et al. Breast Cancer Research 2012; 14:R91
6. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356:881-887.
7. Yamazawa K, Miyazawa Y, Suzuki M, Wakabayashi M, Kaku H, Matsui H, Sekiya S. Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer. Surg Today. 2006; 36(1):41-6.
8. Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012; 38(4):318-28.
9. Gizzo S, Di Gangi S, Bertocco A, Noventa M, Fagherazzi S, Ancona E, Saccardi C, Patrelli TS, D'Antona D, Nardelli GB. Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment: Balance of Breast Risks and Endometrial Benefits--Systematic Review of Literature. Reprod Sci. 2013; [Epub ahead of print]
10. Lindahl B, Andolf E, Ingvar C, Ranstam J, Willén R. Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. Anticancer Res. 2008; 28:1259-62.
11. Behtash N, Hashemi R, Karimi Zarchi M. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev. 2009; 10(1):163-6.
12. Katase K, Sugiyama Y, Hasumi K, Yoshimoto M, Kasumi F. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 1998; 82(9):1698-703.
13. Ho ML, Liaw YP, Lai CH, Chen YY, Tsai HD, Chou MC, Hsiao YH. Significantly increased medical expenditure on breast cancer failing to bring down its mortality and incidence rate. J Cancer. 2013;4(7):531-5